One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with ...

Quest Partners LLC lessened its stake in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 86.2% in the 3rd quarter, ...

Together, these hormones regulate body temperature, heart rate, and metabolism. They also promote growth, development, and maturation of the brain and nervous system. Antibodies serve a purpose in ...

After hours: November 29 at 3:21 PM EST Loading Chart for IGMS ...

2208.HK Goldwind Science&Technology Co., Ltd.

This valuable study proposes a novel rapid-entry mechanism of S. aureus that involves the rapid release of calcium from lysosomes. The strength of the paper lies in a very interesting hypothesis; what ...